MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index
MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index
复制标题
DOI：
10.1093/carcin/bgq051
复制
发表时间：
2010-05-01
期刊：
影响因子：
4.7
通讯作者：
Taioli, Emanuela
中科院分区：
文献类型：
--
作者：
Langevin, Scott M.;Stone, Roslyn A.;Taioli, Emanuela
在美国，头颈癌占所有新发恶性肿瘤的3.3%，占癌症死亡的2.0%，其中大多数是鳞状细胞癌。总的5年生存率为60%，并且随着诊断时分期的增加而增加。因此，需要用于头颈部鳞状细胞癌（SCCHN）早期检测的新生物标志物。microRNA-137（miR-137）在细胞周期调控中起作用，并且似乎在口腔鳞状细胞癌组织中经历启动子甲基化。本研究的主要目的是确定口腔冲洗液样本中是否可检测到miR-137启动子甲基化，评估其与SCCHN的相关性，并确定其发生的潜在风险因素。从99名无癌症既往史的SCCHN患者和99名无癌症对照组中收集口腔冲洗液样本，频率与性别匹配;还检测了64名患者的肿瘤组织。使用甲基化特异性聚合酶链反应评估的miR-137启动子甲基化，在SCCHN患者的21.2%口腔冲洗液和对照组的3.0%中检测到[比值比（OR）= 4.80，95%置信区间（CI）：1.23-18.82]。在病例中，miR-137启动子甲基化与女性性别相关（OR = 5.30，95%CI：1.20-23.44），与体重指数（BMI）呈负相关（OR = 0.88，95%CI：0.77-0.99）。miR-137的启动子甲基化似乎是SCCHN患者口腔冲洗液中相对频繁检测到的事件，并且可能在未来用作DNA甲基化组中的生物标志物。观察到的与性别和BMI的相关性有助于揭示SCCHN甲基化状态改变的潜在风险因素。
Head and neck cancer represents 3.3% of all new malignancies and 2.0% of cancer deaths in the USA, the majority of which are squamous in origin. The overall 5 year survival is 60% and worsens with increasing stage at diagnosis. Thus, novel biomarkers for early detection of squamous cell carcinoma of the head and neck (SCCHN) are needed. MicroRNA-137 (miR-137) plays a role in cell cycle control and seems to undergo promoter methylation in oral squamous cell carcinoma tissue. The main objectives of this study were to ascertain whether miR-137 promoter methylation is detectable in oral rinse samples, assess its association with SCCHN and identify potential risk factors for its occurrence. Oral rinse samples were collected from 99 SCCHN patients with no prior history of cancer and 99 cancer-free controls, frequency matched on gender; tumor tissue for 64 patients was also tested. Methylation of the miR-137 promoter, assessed using methylation-specific polymerase chain reaction, was detected in 21.2% oral rinses from SCCHN patients and 3.0% from controls [odds ratio (OR) = 4.80, 95% confidence interval (CI): 1.23-18.82]. Among cases, promoter methylation of miR-137 was associated with female gender (OR = 5.30, 95% CI: 1.20-23.44) and inversely associated with body mass index (BMI) (OR = 0.88, 95% CI: 0.77-0.99). Promoter methylation of miR-137 appears to be a relatively frequently detected event in oral rinse of SCCHN patients and may have future utility as a biomarker in DNA methylation panels. The observed associations with gender and BMI help to shed light on potential risk factors for an altered methylation state in SCCHN.